PEGBIO CO-B(02565): cornerstone investors voluntarily extend lock-up period.

date
20:40 26/11/2025
avatar
GMT Eight
PegBioPharma-B (02565) announced recently that the company has received a notification from Benefactor Kangray Medicine (Hong Kong) Limited (cornerstone investor). The cornerstone investor has agreed not to reduce its holdings of any related H shares in any way from the original expiration date of the lock-up period until December 31, 2025 (lock-up extension). The company believes that the extension of the lock-up period indicates that the cornerstone investor is confident in the company's future prospects based on the company's research and development capabilities in advancing technology and significant progress in major clinical milestones. The cornerstone investor will also continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and milestones achieved.
PEGBIO CO-B (02565) announcement, recently, the Company has received a notification from Benefactor Concord Pharmaceuticals (Hong Kong) Limited (cornerstone investor), stating that the cornerstone investor has agreed not to reduce its holdings of any related H shares in any way from the original end of the lock-up period to December 31, 2025 (lock-up extension). The Company believes that the extension of the lock-up period shows the cornerstone investor's confidence in the Company's future prospects based on the Company's R&D capabilities in advancing technology and significant progress in major clinical milestones. The cornerstone investor will continue to review the Company's performance and may consider further extending the lock-up period based on real-time developments and milestones achieved.